矿物质皮质类受体抗剂与脏损伤之间的关联:随机对照试验的系统审查和元分析
Satoru Mitsuboshi1, Makoto Morizumi2, Shungo Imai3
1Department of Pharmacy, Kaetsu Hospital, Niigata, Japan.
矿物皮类受体抗剂 (MRA) 不会增加急性损伤 (AKI) 的风险. 然而,像canrenone和spironolactone这样的特定MRA与整体损伤的更高风险有关.
科学领域:
- 腎病學和心臟病學.
- 药理学和治疗学 药理学和治疗学
背景情况:
- 关于矿物质皮质类受体抗剂 (MRA) 和急性损伤 (AKI) 之间的关联,存在相互矛盾的证据.
- 本系统性审查和元分析解决了MRAs对心血管或脏疾病患者脏健康影响的不确定性.
结论:
- 与MRA相关的损伤风险可能取决于使用的特定药物.
- 需要进一步的研究来区分单个MRA的安全性.
- 精心选择MRA对于管理心脏或脏疾病患者至关重要,以尽量减少与脏相关的风险.
更多相关视频
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
